Stay updated on VAX-24 Safety and Immunogenicity in Adults Clinical Trial
Sign up to get notified when there's something new on the VAX-24 Safety and Immunogenicity in Adults Clinical Trial page.

Latest updates to the VAX-24 Safety and Immunogenicity in Adults Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe page has undergone significant updates, including the addition of new details about the VAX-24 pneumococcal vaccine and its clinical study design, while removing extensive descriptions of the study's objectives and criteria.SummaryDifference26%
- Check41 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check84 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check99 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check106 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to VAX-24 Safety and Immunogenicity in Adults Clinical Trial
Enter your email address, and we'll notify you when there's something new on the VAX-24 Safety and Immunogenicity in Adults Clinical Trial page.